BGI NOVA™ Newborn Genetic Screening
Introduction
Each year, an estimated 7.9 million babies worldwide are born with birth defects, many of which appear healthy at birth and come from families with no history of the disorder. Many affected babies are not identified until the appearance of severe and often irreversible symptoms later in life.
Detecting a disease at an early stage can enable appropriate and timely medical intervention before more serious and sometimes irreversible health issues are caused.
BGI’s NOVA™ Newborn Genetic Screening Test determines a baby’s risk for 87 inherited disorders, as well as providing personalized genetic information on the likely response of 32 pediatric drugs.
Why Choose BGI NOVA™ Newborn Genetic Screening?
- Fast-15 working days to get your genetic report
- Accurate-Targeted region capture based NGS with proprietary database
- Affordable-Lower price for every family
Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients/guardians should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.
Conditions Screened
INHERITED DISORDERS | 87 |
Amino Acid Metabolism Disorders | 20 |
Fatty Acid Oxidation Disorders | 16 |
Organic Acid Disorders | 13 |
Carbohydrate Disorders | 3 |
Creatine Metabolism Disorders | 1 |
Lysosomal Storage Disease | 10 |
Copper Metabolism Disorder | 2 |
Primary Immunological Deficiency | 14 |
Blood Lipid Disorders | 3 |
Miscellaneous Genetic Conditions | 5 |
PAEDIATRIC PHARMACOGENOMICS | 32 |
Neurology drugs | 11 |
Anti-infection agents | 10 |
Cancer Drugs | 2 |
Rheumatism drugs | 1 |
Cardiovascular drugs | 3 |
Gastroenterology drugs | 3 |
Others | 2 |
Workflow
Ordering BGI NOVA™ Newborn Genetic Screening is easy.
